Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP).

Critically ill adolescents are at greatest risk for developing hospital-acquired venous thromboembolism. To date, no phase 3 randomized controlled trials have been conducted for pharmacological thromboprophylaxis as primary venous thromboembolism prevention in children. The investigators will perform a United States definitive multicenter phase 3 randomized controlled trial of the low molecular weight heparin enoxaparin as primary venous thromboembolism prophylaxis among critically ill adolescents who are classified a priori as high risk based upon the investigators validated risk prediction models.

NCT Number	NCT06628778
Lead Sponsor	Johns Hopkins All Children's Hospital Collaborators: University of California, San Diego
Conditions	Venous Thromboembolism (VTE)
Enrollment	802 participants
Start Date	2027-04-15
Primary Completion	2034-04-15 (estimated)
Study Completion	2035-04-15 (estimated)
Updated on ClinicalTrials.gov	2026-05-26